Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Preferred Stock Liabilities: 2014

  • Zevra Therapeutics' Preferred Stock Liabilities was N/A to $24.2 million in Q4 2014 from the same period last year, while for Dec 2014 it was $24.2 million, marking a year-over-year change of. This contributed to the annual value of $24.2 million for FY2014, which is 30.51% up from last year.
  • According to the latest figures from Q4 2014, Zevra Therapeutics' Preferred Stock Liabilities is $24.2 million.
  • Zevra Therapeutics' Preferred Stock Liabilities' 5-year high stood at $24.2 million during Q4 2014, with a 5-year trough of $24.2 million in Q4 2014.
  • In the last 1 years, Zevra Therapeutics' Preferred Stock Liabilities had a median value of $24.2 million in 2014 and averaged $24.2 million.